Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald A Rowley

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Science (New York, N.Y.)|January 12, 2008
Cancer. Quo vadis, specificity?Hans Schreiber, Donald A Rowley
Science (New York, N.Y.)|November 6, 2010
Cancer. Awakening immunityHans Schreiber, Donald A Rowley
Cellular Immunology|February 14, 2012
The road to the discovery of dendritic cells, a tribute to Ralph SteinmanDonald A Rowley, Frank W Fitch
Seminars in Cancer Biology|January 4, 2012
Targeting stroma to treat cancersBoris Engels, Donald A Rowley, Hans Schreiber
Seminars in Cancer Biology|October 19, 2004
Inflammation as a tumor promoter in cancer inductionMary Philip, Donald A Rowley, Hans Schreiber
Blood|July 30, 2011
Targeting mutations predictablyHans Schreiber, Janet D Rowley, Donald A Rowley
Nature Medicine|February 26, 2004
Bystander elimination of antigen loss variants in established tumorsMichael T Spiotto, Donald A Rowley, Hans Schreiber
Clinical Transplantation|August 25, 2010
Prevention of renal allograft rejection without immune suppression: a model to revisitDonald A Rowley, Frank P Stuart, Frank W Fitch
The Journal of Clinical Investigation|March 5, 2008
IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancersBin Zhang, Theodore Karrison, Donald A Rowley, et al.
European Journal of Immunology|February 21, 2003
C-kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serumChristian Beck, Karin Schreiber, Hans Schreiber, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Science (New York, N.Y.)|January 12, 2008
Cancer. Quo vadis, specificity?Hans Schreiber, Donald A Rowley
Science (New York, N.Y.)|November 6, 2010
Cancer. Awakening immunityHans Schreiber, Donald A Rowley
Cellular Immunology|February 14, 2012
The road to the discovery of dendritic cells, a tribute to Ralph SteinmanDonald A Rowley, Frank W Fitch
Seminars in Cancer Biology|January 4, 2012
Targeting stroma to treat cancersBoris Engels, Donald A Rowley, Hans Schreiber
Seminars in Cancer Biology|October 19, 2004
Inflammation as a tumor promoter in cancer inductionMary Philip, Donald A Rowley, Hans Schreiber
Blood|July 30, 2011
Targeting mutations predictablyHans Schreiber, Janet D Rowley, Donald A Rowley
Nature Medicine|February 26, 2004
Bystander elimination of antigen loss variants in established tumorsMichael T Spiotto, Donald A Rowley, Hans Schreiber
Clinical Transplantation|August 25, 2010
Prevention of renal allograft rejection without immune suppression: a model to revisitDonald A Rowley, Frank P Stuart, Frank W Fitch
The Journal of Clinical Investigation|March 5, 2008
IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancersBin Zhang, Theodore Karrison, Donald A Rowley, et al.
European Journal of Immunology|February 21, 2003
C-kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serumChristian Beck, Karin Schreiber, Hans Schreiber, et al.
Pageof 3